Biotherapies for Parkinson disease.
Identifieur interne : 000470 ( PubMed/Corpus ); précédent : 000469; suivant : 000471Biotherapies for Parkinson disease.
Auteurs : P. RemySource :
- Revue neurologique [ 0035-3787 ] ; 2014.
English descriptors
- KwdEn :
- MESH :
- chemical , biosynthesis : Dopamine.
- methods : Biological Therapy, Cell Transplantation, Genetic Therapy, Immunotherapy.
- chemical , therapeutic use : Intercellular Signaling Peptides and Proteins.
- therapy : Parkinson Disease.
- Animals, Humans.
Abstract
The clinical use of biotherapies in Parkinson disease already has 30 years' history. The transplantation of dopamine fetal cells in the striatum of advanced patients has proved to be relevant in some patients but randomized efficacy trials in the US have provided disappointing results. However, cell therapies might come back on stage with the use of stem cells in the future. Gene therapy is a more recent strategy relying on viral vectors able to transduce genes coding either for the enzymes that can increase neurotransmitters production or genes for trophic factors. Several approaches have been developed in PD and have been experimented in patients. Although, some of the studies have evidenced insufficient clinical benefit, other programs, such as those using dopamine replacement techniques are promising. We find fresh hope in this field that might be the future of PD treatment. It remains however that advanced PD might not be the ideal condition to properly benefit from biotherapies and there is a need of studies at earlier stages of the disease, a time where major change in the disease course might be expected.
DOI: 10.1016/j.neurol.2014.10.002
PubMed: 25459116
Links to Exploration step
pubmed:25459116Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biotherapies for Parkinson disease.</title><author><name sortKey="Remy, P" sort="Remy, P" uniqKey="Remy P" first="P" last="Remy">P. Remy</name><affiliation><nlm:affiliation>Centre expert Parkinson, neurologie, université Paris-Est, CHU Henri-Mondor, AP-HP, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Équipe 2, MIRCEN, CEA/DSV/I2BM, 18, route du Panorama, bâtiment 61, 92265 Fontenay-aux-Roses cedex, France; NEURATRIS, MIRCen, 18, route du Panorama I, bâtiment 61, pièce 121, BP 6 I, 92265 Fontenay-aux-Roses cedex, France. Electronic address: neuro-philippe.remy@hmn.aphp.fr.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25459116</idno><idno type="pmid">25459116</idno><idno type="doi">10.1016/j.neurol.2014.10.002</idno><idno type="wicri:Area/PubMed/Corpus">000470</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000470</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Biotherapies for Parkinson disease.</title><author><name sortKey="Remy, P" sort="Remy, P" uniqKey="Remy P" first="P" last="Remy">P. Remy</name><affiliation><nlm:affiliation>Centre expert Parkinson, neurologie, université Paris-Est, CHU Henri-Mondor, AP-HP, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Équipe 2, MIRCEN, CEA/DSV/I2BM, 18, route du Panorama, bâtiment 61, 92265 Fontenay-aux-Roses cedex, France; NEURATRIS, MIRCen, 18, route du Panorama I, bâtiment 61, pièce 121, BP 6 I, 92265 Fontenay-aux-Roses cedex, France. Electronic address: neuro-philippe.remy@hmn.aphp.fr.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Revue neurologique</title><idno type="ISSN">0035-3787</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Biological Therapy (methods)</term><term>Cell Transplantation (methods)</term><term>Dopamine (biosynthesis)</term><term>Genetic Therapy (methods)</term><term>Humans</term><term>Immunotherapy (methods)</term><term>Intercellular Signaling Peptides and Proteins (therapeutic use)</term><term>Parkinson Disease (therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Biological Therapy</term><term>Cell Transplantation</term><term>Genetic Therapy</term><term>Immunotherapy</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Intercellular Signaling Peptides and Proteins</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The clinical use of biotherapies in Parkinson disease already has 30 years' history. The transplantation of dopamine fetal cells in the striatum of advanced patients has proved to be relevant in some patients but randomized efficacy trials in the US have provided disappointing results. However, cell therapies might come back on stage with the use of stem cells in the future. Gene therapy is a more recent strategy relying on viral vectors able to transduce genes coding either for the enzymes that can increase neurotransmitters production or genes for trophic factors. Several approaches have been developed in PD and have been experimented in patients. Although, some of the studies have evidenced insufficient clinical benefit, other programs, such as those using dopamine replacement techniques are promising. We find fresh hope in this field that might be the future of PD treatment. It remains however that advanced PD might not be the ideal condition to properly benefit from biotherapies and there is a need of studies at earlier stages of the disease, a time where major change in the disease course might be expected.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25459116</PMID><DateCreated><Year>2014</Year><Month>12</Month><Day>09</Day></DateCreated><DateCompleted><Year>2015</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2014</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Internet"><Volume>170</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation></Journal><ArticleTitle>Biotherapies for Parkinson disease.</ArticleTitle><Pagination><MedlinePgn>763-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2014.10.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0035-3787(14)01010-8</ELocationID><Abstract><AbstractText>The clinical use of biotherapies in Parkinson disease already has 30 years' history. The transplantation of dopamine fetal cells in the striatum of advanced patients has proved to be relevant in some patients but randomized efficacy trials in the US have provided disappointing results. However, cell therapies might come back on stage with the use of stem cells in the future. Gene therapy is a more recent strategy relying on viral vectors able to transduce genes coding either for the enzymes that can increase neurotransmitters production or genes for trophic factors. Several approaches have been developed in PD and have been experimented in patients. Although, some of the studies have evidenced insufficient clinical benefit, other programs, such as those using dopamine replacement techniques are promising. We find fresh hope in this field that might be the future of PD treatment. It remains however that advanced PD might not be the ideal condition to properly benefit from biotherapies and there is a need of studies at earlier stages of the disease, a time where major change in the disease course might be expected.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Remy</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre expert Parkinson, neurologie, université Paris-Est, CHU Henri-Mondor, AP-HP, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Équipe 2, MIRCEN, CEA/DSV/I2BM, 18, route du Panorama, bâtiment 61, 92265 Fontenay-aux-Roses cedex, France; NEURATRIS, MIRCen, 18, route du Panorama I, bâtiment 61, pièce 121, BP 6 I, 92265 Fontenay-aux-Roses cedex, France. Electronic address: neuro-philippe.remy@hmn.aphp.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001691" MajorTopicYN="N">Biological Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017690" MajorTopicYN="N">Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Avis</Keyword><Keyword MajorTopicYN="N">Gene therapy</Keyword><Keyword MajorTopicYN="N">Graft</Keyword><Keyword MajorTopicYN="N">Greffe</Keyword><Keyword MajorTopicYN="N">La thérapie génique</Keyword><Keyword MajorTopicYN="N">La transplantation</Keyword><Keyword MajorTopicYN="N">Review</Keyword><Keyword MajorTopicYN="N">Transplantation</Keyword><Keyword MajorTopicYN="N">Vecteurs viraux</Keyword><Keyword MajorTopicYN="N">Viral vector</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25459116</ArticleId><ArticleId IdType="pii">S0035-3787(14)01010-8</ArticleId><ArticleId IdType="doi">10.1016/j.neurol.2014.10.002</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000470 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000470 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25459116
|texte= Biotherapies for Parkinson disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25459116" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |